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Health care workers (HCW) are a high-risk population to acquire SARS-CoV-2 infection from
patients or other fellow HCW. This study aims at estimating the seroprevalence against
SARS-CoV-2 in a random sample of HCW from a large hospital in Spain. Of the 578 parti-
cipants recruited from 28 March to 9 April 2020, 54 (9.3%, 95% CI: 7.1–12.0) were ser-
opositive for IgM and/or IgG and/or IgA against SARS-CoV-2. The cumulative prevalence of
SARS-CoV-2 infection (presence of antibodies or past or current positive rRT-PCR) was
11.2% (65/578, 95% CI: 8.8–14.1). Among those with evidence of past or current infection,
40.0% (26/65) had not been previously diagnosed with COVID-19. Here we report a rela-
tively low seroprevalence of antibodies among HCW at the peak of the COVID-19 epidemic in
Spain. A large proportion of HCW with past or present infection had not been previously
diagnosed with COVID-19, which calls for active periodic rRT-PCR testing in hospital settings.
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COVID-19 is a novel viral disease caused by SARS-CoV-2that was first detected in Wuhan, China, in December20191. Given the alarming levels of spread, severity of
disease, and number of affected countries, the World Health
Organization (WHO) declared COVID-19 as a pandemic on
March 11th, 20202. The clinical syndrome caused by SARS-CoV-
2 ranges from very mild symptomatology to severe pneumonia,
acute respiratory distress syndrome, and death3. However, several
reports show that many individuals might carry the virus without
presenting any symptoms for several weeks4–6. Thus, the exact
number of individuals who have been infected by SARS-CoV-2 is
currently unknown.
Health care workers (HCW) are the frontline workforce for
clinical care of suspected and confirmed COVID-19 cases. Con-
sequently, they are presumably exposed to a higher risk of
acquiring the disease than the general population and, if infected,
pose a risk to vulnerable patients and fellow HCW7. In a tertiary
hospital in Madrid, Spain (one of the regions with the highest
COVID-19 attack rates in the country), 38% (791/2085) of HCW
tested positive for SARS-CoV-2 by real-time reverse-transcriptase
polymerase chain reaction (rRT-PCR) in March 2020 (11.6% of
all hospital workers)8. HCW with a positive rRT-PCR diagnosis
need to be isolated, and their close contacts—many of them co-
workers—should be quarantined. Thus, if transmission rises, the
number of frontline HCW could become insufficient to respond
to the healthcare demand. To cope with this scenario, several
strategies, including periodic screenings, weekly-shifts, and other
organizational measures are being implemented in a variety of
settings to guarantee proper patient care9. Nonetheless, quanti-
fication and characterization of SARS-CoV-2 infection within
health care facilities is unknown in most countries hard-hit by the
COVID-19 epidemic.
Seroprevalence studies can provide relevant information on the
proportion of people who have experienced a recent or past
infection. They are relevant when conducted in the community,
but also for critical population subgroups such as nursing homes
or health care facilities. Monitoring the prevalence of infection
among HCW (regardless of history of symptoms) is useful for
assessing the level of exposure among hospital personnel and
identifying high-risk departments. Likewise, knowledge of past
infection among HCW could be useful for avoiding unnecessary
quarantines and for health care resource planning10. Although
there is a growing body of evidence on the immunological
responses against SARS-CoV-2, the time to seroconversion and
the antibody levels elicited are not well characterized yet.
Importantly, the correlation between seropositivity or antibody
levels and protection against reinfection, as well as the duration of
protective immunity, remains to be elucidated11.
This study aims to estimate the seroprevalence of antibodies
against SARS-CoV-2 and characterize the antibody profile in
HCW from Hospital Clínic of Barcelona (HCB), one of the
reference centers in Spain for the diagnosis and treatment of
COVID-19 disease. As a secondary objective, we aim to assess the
overall infection prevalence (past and current) to SARS-CoV-2 as
well as the prevalence of asymptomatic infections.
Results
Baseline characteristics. From a total number of 5598 HCW
registered at HCB as of March 9th 2020, we approached the first
1172 randomly selected individuals, following the order of the list.
Of these, 798 were eligible to participate and 583 were recruited,
yielding a participation rate of 74.3%. We then excluded five
recruited participants after re-checking inclusion and exclusion
criteria (Fig. 1). A total of 578 participants were included in the
analysis, of whom 314 (54.3%) were younger than 45 years of age.
The mean age of participants was 42.1 years (SD: 11.6) and 72.1%
were female. Around half (288/578, 49.8%) were nurses, auxiliary
nurses or stretcher-bearers, and 25.4% (147/578) were physicians.
Eleven per cent of the participants reported having comorbidities
and 36.3% reported having had COVID-19-compatible symptoms
in the previous months. Thirty-nine participants (6.7%) had been
previously diagnosed with COVID-19 confirmed by rRT-PCR, of
which only one had required hospital admission (Table 1 and
Supplementary Table 1).
Fig. 1 Study participant flowchart.
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Prevalence of current infection as determined by a positive
rRT-PCR. Fifteen participants (2.6%, 95% CI: 1.5–4.3%) had a
positive rRT-PCR of SARS-CoV-2 at the time of recruitment and
0.003 had an invalid rT-PCR result. Among participants with a
positive rRT-PCR at recruitment, 9 of 15 (60.0%) had a previous
COVID-19 diagnosis, and 3 of 15 (20.0%) did not report any
COVID-19-compatible symptom in the previous months. The
mean time since diagnosis among those participants with a pre-
vious COVID-19 diagnosis and a positive rRT-PCR at recruit-
ment was 9 days (range 2–17). Only 1 of the 6 participants with
positive rRT-PCR at recruitment and no history of previous
COVID-19 diagnosis had detectable antibodies.
Seroprevalence of antibodies against SARS-CoV-2. Fifty-four
participants (9.3%, 95% CI: 7.1–12.0) were seropositive for IgM
and/or IgG and/or IgA against SARS-CoV-2 (Table 2). A total of
36 (6.2%), 44 (7.6%), and 47 (8.1%) participants were positive for
IgM, IgG, and IgA, respectively (Fig. 2). Four participants were
seropositive for IgM only (IgG- & IgA-), two were seropositive for
IgG only (IgM- & IgA-), and five were seropositive for IgA only
(IgG- & IgM-). Around 15% (6/39) of HCW who had been
previously diagnosed with COVID-19 by rRT-PCR did not show
a detectable response of any of the antibody isotypes (Supple-
mentary Table 2). However, the days since onset of symptoms to
recruitment were <10 in 4 out of the 6 individuals without
detectable antibodies and one individual had no symptoms.
Twenty per cent (11/54) of seropositive participants did not
report COVID-19 compatible symptoms in the previous months.
Around 39% (21/54) of seropositive HCW had never been
diagnosed of COVID-19, although 10 of these (47.6%) reported
past COVID-19-compatible symptoms.
The odds of being seropositive were higher in participants who
reported having had any COVID-19-compatible symptom in the
previous months (adjusted OR: 8.8, 95% CI 4.41–17.73, p <
0.0001) (Table 3). The individual symptoms more strongly
associated with seropositivity were (in order): anosmia (OR: 83.0,
95% CI: 29.6–232.9), ageusia (OR: 71.4, 95% CI: 25.4–200.8),
fever (OR: 11.4, 95% CI: 6.0–31.3) and fatigue (OR: 11.2, 95% CI:
6.1–20.7), all of them with a p < 0.0001 in the univariable analysis.
There was some evidence in the multivariable logistic regression
models (MLM) that those with higher household size had higher
odds of being seropositive (OR for every additional household
member: 1.3; 95% CI: 0.96–1.62; p value (Wald test)= 0.09). The
professional category, working in COVID-19 units, daily contact
with patients, close contact with a COVID-19 case, comorbidities
or sex, did not show any statistically significant association with
presence of antibodies to SARS-CoV-2 (Table 3, Supplementary
Fig. 2).
Among seropositive HCW, there were no statistically sig-
nificant associations of antibody levels with sex (Fig. 3a). IgM
levels positively correlated with age (rho= 0.36, p value (Spear-
man)= 0.031) (Fig. 3b). IgA levels were higher in participants
reporting COVID-19-compatible symptoms in the previous
months than in those reporting being asymptomatic (p= 0.041)
(Fig. 3c), and among symptomatic individuals, duration of
symptoms >10 days was associated with higher IgM levels (p=
0.022) (Fig. 3d).
Among HCW reporting symptoms in the last months,
antibodies were detected in individuals with 6 or more days
between symptoms onset and recruitment for IgA and later for
IgM and IgG (Fig. 4), with no seropositive results detected among
individuals with symptoms onset <6 days prior to the recruitment
visit. In fact, we only detected antibodies in two participants
surveyed <10 days after onset of symptoms (Supplementary
Table 3). Antibody levels increased and peaked between day 20
Table 2 Overall proportion of HCW with (a) detectable antibodies, (b) history of past positive rRT-PCR, (c) Positive rRT-PCR at
study recruitment, and (d) Cumulative prevalence of infection (past/current rRT-PCR and/or antibodies).
n Total % (95% CI) Not previously diagnosed as COVID-19
by rRT-PCR (n (%))
COVID19-symptoms
reporteda n (%)
Seropositive to SARS CoV-2 Antibodies (IgA
and/or IgM and/or IgG)
54 578 9.3% (7.1–12.0) 21 (38.9%) 10 (47.6%)
Positive rRT-PCR at study recruitmentb 15 576 2.6% (1.5–4.3) 6 (42.9%) 3 (50.0%)
Any evidence of past/current infection by
rRT-PCR of serology
65 578 11.2% (8.8–14.1) 26 (40.0%) 12 (46.2%)
aAmong those not previously diagnosed as COVID-19 (from previous column).
bResults of 42 of the 578 rRT-PCRs done were invalid (Ct≥ 40 for RNase P).
Table 1 Baseline characteristics of study participants.
Total













Daily contact with patientsa No 123 (21%)
Yes 455 (79%)
Working in a COVID-19 unita No 315 (54%)
Yes 263 (46%)
Close contact with confirmed







Comorbiditiesa,d No 517 (89%)
Yes 61 (11%)











bIncludes, cleaning, kitchen and maintenance staff.
cArithmetic Mean (SD) [n].
dComorbidities include: heart and liver disease, diabetes, chronic respiratory and renal disease,
cancers and autoimmune, and other immunological disorders.
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and 25 for IgM and IgG, and a few days earlier for IgA. There
were only three seropositive HCW with symptoms onset having
occurred earlier than 25 days prior to survey (Supplementary
Table 3).
Overall cumulative prevalence of past or current infection.
Sixty-five HCW had either a positive rRT-PCR in the past or at
survey recruitment, or had a positive antibody response (Table 2).
Thus, the cumulative prevalence of SARS-CoV-2 infection was
11.2% (95% CI: 8.8–14.1). Among them, 23.1% (15/65) did not
report any COVID-19 compatible symptom in the previous
months. Forty per cent (26/65) had not been previously diag-
nosed with COVID-19, although 12 of them reported COVID-19
compatible symptoms.
Discussion
This is, to our knowledge, the first study reporting seroprevalence
of antibodies against SARS-CoV-2 among a representative sample
of HCW in a COVID-19 high burden country. We found that
9.3% (95% CI: 7.2–12.0) of HCW from a large Spanish referral
hospital (recruited from March 28th to April 9th, 2020) devel-
oped detectable IgA, IgG, and/or IgM antibodies. Given that
HCW are a high-risk population for SARS-CoV-2, it is likely that
the community seroprevalence is lower than this figure, showing
that we are still very far from reaching the 67% herd immunity
level that is estimated to be needed to protect the susceptible
population12, assuming that this immunity prevents from rein-
fection. The seroprevalence found was lower than expected, based
on the large number of rRT-PCR positive cases reported in a
referral hospital in Madrid in March 2020 (11.6% of all hospital
workers)8, and an estimate from modeling studies of 15%
seroprevalence for the overall Spanish population in March
202013. However, it is compatible with the 7.1% (95% CI:
5.9–8.5%) preliminary seroprevalence results for Barcelona pro-
vince, as reported by the national Ministry of Science in the
period 27 April–11 May 202014. The likely higher availability of
PPE compared with other hospitals, and the early implementa-
tion of rRT-PCR screening programs in HCW working in
COVID-19 units, coupled with timely case identification and
effective contact tracing and quarantines for those outside
COVID-19 unit, could explain a relatively low number of infec-
tions in our study.
Combining data from antibody detection and previous or
current positive rRT-PCR, the cumulative prevalence of SARS-
CoV-2 infection rose to 11.2%. However, 40.0% of the ser-
opositive HCW had not previously been diagnosed with COVID-
19 and 23.1% were asymptomatic, indicating a large percentage of
infections were undetected15. This calls for early detection/
screening programs to be broadly and timely implemented in
HCW to decrease in-hospital transmission as well as reinforce the
critical role of PPE usage16.
The likelihood of being seropositive was higher in participants
who reported having had any COVID-19 symptom within the
last months (OR: 8.84) and 80% of seropositive HCW did report
having had symptoms. Although most COVID-19 symptoms are
common to many other upper respiratory viral infections, those
more highly associated with seropositivity were by far anosmia
and ageusia (both OR > 70) that, although infrequent, seem to be
quite specific for COVID-1917,18. As expected, having developed
the disease was the most important factor associated with the
development of antibodies (OR: 135.6). In addition, there was
some evidence that the higher the size of the household, the
higher the odds (OR: 1.25) of being seropositive (p < 0.09),
potentially because household exposure is an added source of
infection among HCW. None of the professional categories or
being directly involved in clinical care were factors associated
with higher odds of being seropositive. Working in a COVID-19
unit was also not associated with seropositivity, which might be
explained by a higher perception of risk leading to a better pro-
tection with PPEs, more careful practices and thus, a lower risk of
acquiring the infection19. Nonetheless, the relatively low number
of seropositive HCW in our sample hinders any firm conclusion
about associations between professional categories, level of
patient interaction, and risk of infection.
Using only the RBD antigen in the assay but three different
isotypes, we could detect antibodies in 97% of participants with a
previous positive rRT-PCR and more than 10 days since onset of
symptoms. This is in line with previous reports showing that
seroconversion occurs between 2–3 weeks after onset of symp-
toms11. Importantly, we detected lower IgA levels in seropositive
participants without symptoms, in line with a previous observa-
tion of correlation of IgA levels and COVID-19 severity (preprint
publication)20. If it is confirmed that asymptomatic subjects have
lower levels of antibodies21, this could impact detection of ser-
oconversion in this specific group. We cannot discard that some
participants may be either very low or non-responders, as several
reports have found COVID-19 patients with low or no responses
for IgM, IgG, or neutralizing antibodies22,23.
By increasing the number of viral antigens in our assay we
may allow to increase its sensitivity, as responses to different
antigens may present different kinetics and vary between indi-
viduals24,25. Nonetheless, we included determinations to three
isotypes to capture a variety of responses between individuals
and their relation to time from onset of symptoms. Also, their
maintenance and role in protection are probably different. IgM is
the first antibody being produced by B cells upon antigenic
Fig. 2 SARS-CoV-2 antibody levels in all study participants. Dots depict
the levels (median fluorescence intensity, MFI) of IgM, IgG, and IgA against
Receptor Binding Domain (RBD) of the SARS-CoV-2 Spike glycoprotein.
Dashed lines indicate the seropositivity threshold calculated with pre-
pandemic controls as the 10 to the mean plus 3 standard deviations of
log10-transformed MFIs. The percentage of seropositive subjects is shown
for each antibody isotype. Orange and burgundy dots show subjects who
did not have or did have history of at least one COVID-19 compatible
symptom, respectively. N= 578.
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encounter, IgA is key for mucosal immunity, and IgG is con-
sidered to be the most important for memory responses, but
their respective kinetics will only be well characterized over a
longitudinal follow-up study. We found few participants with
IgA only, IgM only, or IgG only, and no evidence that specific
antibody profiles are associated with the onset of symptoms or
current positive rRT-PCR. Therefore, our data do not support
that antibody responses could contribute to diagnosis of acute
infection (IgM detection ± increasing IgG) versus past infection
(negative or low IgM and persisting IgG) as previously sug-
gested26. However, our analysis of antibody levels and ser-
oprevalence by days since onset of symptoms suggests that IgA
responses can be detected and peak earlier than IgM and IgG,
consistent with previous reports27.
This study has several limitations. First, we collected data over
a 12-day period, which, in the context of a rapidly growing epi-
demic, hinders its association to a specific date, with the pre-
valence having to be interpreted as the average prevalence over
those 12 days. Second, we only collected nasopharyngeal samples
(instead of oropharyngeal and nasopharyngeal) from study
participants for the molecular detection of SARS-CoV-2 RNA.
Although this could reduce rRT-PCR sensitivity, there is evidence
showing that nasopharyngeal samples have a higher positivity
rate than oropharyngeal samples28. Third, seroprevalence was
defined as positivity of any of the antibody isotypes (IgM, IgG,
and IgA), which maximized sensitivity rather than specificity.
However, our Luminex assay validation showed excellent speci-
ficity for the three isotypes, thus, our potential overestimation of
the true prevalence is likely to be minimized. Finally, our parti-
cipation rate (74%) could have introduced selection bias in our
sample. It could be that many of those refusing to participate
might have had a characteristic associated to an increased risk of
infection (being very busy at COVID-19 units, for example).
Thus, the impact is potentially minimal, given the lack of asso-
ciation of this and most studied variables with our primary
endpoint.
In conclusion, the seroprevalence of antibodies to SARS-CoV-2
was lower than expected. Most participants with a confirmed
COVID-19 diagnosis elicited antibody responses (IgA, IgG and/
or IgM), with IgA demonstrating the highest sensitivity in the
Table 3 Univariable and multivariable analysis of factors associated with having detectable antibodies (IgM and/or IgG and/
or IgA).





P value OR (95% CI) p value OR (95% CI) p value
Sexa Male 148 (28%) 13 (24%) 0.52b 1 0.52
Female 376 (72%) 41 (76%) 1.24 (0.65; 2.38)
Agec,d 42 (12) 40 (12) 0.11e 0.98 (0.96; 1.00) 0.11 0.98 (0.95; 1.00) 0.09f








262 (50%) 26 (48%) 1.12 (0.49; 2.55)
Physicians 131 (25%) 16 (30%) 1.37 (0.56; 3.35)
Daily contact with
patientsa
No 113 (22%) 10 (19%) 0.60b 1 0.60
Yes 411 (78%) 44 (81%) 1.21 (0.59; 2.48)
Working in a COVID-19
unita
No 284 (54%) 31 (57%) 0.65b 1 0.65




No 127 (24%) 10 (19%) 0.35b 1 0.35
Yes 397 (76%) 44 (81%) 1.41 (0.69; 2.88)
Previously diagnosed
with COVID-19 by rRT-
PCRa
No 518 (99%) 21 (39%) <0.0001j 1 <0.0001
Yes 6 (1%) 33 (61%) 135.67 (51.27; 359.01)
Comorbiditiesa,h No 471 (90%) 46 (85%) 0.28b 1 0.29
Yes 53 (10%) 8 (15%) 1.55 (0.69; 3.45)
Household sizec,d 2.7 (1.2) 2.9 (1.1) 0.37e 1.11 (0.88; 1.41) 0.37 1.25 (0.96; 1.62) 0.09f
Received Flu vaccine
(2019–2020 season)a
No 309 (59%) 30 (56%) 0.63b 1 0.63





No 357 (68%) 11 (20%) <0.0001b 1 <0.0001 1 <0.0001f
Yes 167 (32%) 43 (80%) 8.36 (4.20; 16.61) 8.84 (4.41; 17.73)
an (Column percentage).
bChi-squared test.
cArithmetic mean (SD) [n].
dOdds ratio per unit increase.
eT-test.
fWald test.
gIncludes, cleaning, kitchen and maintenance staff.
hComorbidities include: heart and liver disease, diabetes, chronic respiratory and renal disease, cancers and autoimmune, and other immunological disorders.
iIncludes strecher-bearer.
jFisher’s exact test.
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initial days after symptoms onset. Given the current lack of evi-
dence on the correlation of SARS-CoV-2 antibody levels and
protection against reinfection, no recommendations should be
derived for seropositive HCW at an individual level. This study
also shows that around 46% of undiagnosed infections occur in
HCW who report having experienced COVID-19 compatible
symptoms. Thus, enforcement of rRT-PCR screening programs
for all HCW, regardless of the presence of symptoms, is highly
recommended in healthcare settings to reduce the risk of
hospital-acquired SARS-CoV-2 infections.
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Methods
Study design, population and setting. The study design consists of four cross-
sectional surveys (at baseline, 1 month, 6 months and 12 months) in the same
cohort of randomly selected HCW from HCB. We hereby present the first cross-
sectional survey, conducted from March 28th to April 9th, 2020. The study
population was defined as those who deliver care and services to patients, either
directly as physicians or nurses, or indirectly as assistants, technicians, stretcher-
bearers, or other support staff (administrative officers, cleaning, kitchen, laundry,
maintenance, etc.)29. Inclusion criteria included being an adult (>17 years) worker
at HCB registered at the Human Resources department. Exclusion criteria inclu-
ded: (a) absenteeism from workplace in the last 30 days (i.e., on vacation, sick leave,
sabbatical), (b) working exclusively outside the HCB or Maternity main buildings
with no interaction with patients on a daily basis, (c) retirement or end-of-contract
planned within one year after the recruitment date, and (d) participating in
COVID-19 clinical trials for preventive or treatment therapies.
HCB is a large University of Barcelona teaching hospital. With over 700 beds, it
is the main public supplier of specialized health services for a population of around
540,000 inhabitants and also acts as a tertiary referral hospital30.
Procedures. A random sample of HCW was selected from the HCB’s Human
Resources database (as of March 9th, 2020). Selected individuals were approached
telephonically following the order of the random list were excluded upon review of
inclusion and exclusion criteria or after three phone calls (different days) without
response.
After obtaining written informed consent, we filled out a standardized
electronic questionnaire programmed in REDCap (Research Electronic Data
Capture)31 for each participant, with the following information: demographics
(age, sex, household size, etc.), professional information (occupation, hospital
department, and shift), clinical information such as history of COVID-19-
compatible symptoms during the previous months (cough, sore throat, runny nose,
fatigue, shortness of breath, fever, headache, vomiting, diarrhea, anosmia, ageusia,
and chills) date of onset and resolution of symptoms, history of rRT-PCR testing,
comorbidities, and history of close contact with COVID-19 cases.
We collected a nasopharyngeal swab (DeltaLabs ref: 304273) for the detection of
SARS-CoV-2 RNA by rRT-PCR and a venous blood draw for immunological
assessments. Both procedures were performed by trained nurses using appropriate
personal protective equipment (PPE). Samples were transported to the laboratory
within 3 h of sample collection. Nasopharyngeal swabs and plasma samples were
stored at −80 °C until analysis.
For participants reporting to be isolated at home (i.e., due to a COVID-19
diagnosis) or on quarantine, data, and specimen collection took place at their
households following the relevant biosafety protocols.
Laboratory procedures. rRT-PCR. After adding 500 μl of Zymo DNA/RNA Shield
Lysis Buffer to the same amount of nasopharyngeal sample collection media, RNA
was extracted using the Quick-DNA/RNA Viral MagBead kit (Zymo) and the
TECAN Dreamprep robot. Five microliters of RNA solution were added to 15 μl of
rRT-PCR master mix (Luna Universal Probe One-Step RT-qPCR Kit; New Eng-
land Biolabs) and used for amplification of SARS-CoV-2 N1 and N2 regions, as
well as the human RNase P gene as control, using probes, primers and cycling
conditions described in the CDC-006-00019 CDC/DDID/NCIRD/ Division of
Viral Diseases protocol (3/30/2020 release, Supplementary Note 1). Each batch of
RNA extractions and rRT-PCR reactions included three positive controls (EURM-
019 single stranded RNA fragments of SARS-CoV-2 provided by the European
Commission Joint Research Centre), 2019-nCoV_N_Positive Control (IDT inte-
grated technologies, ref. 10006625) and Hs_RPP30 Positive Control (IDT inte-
grated technologies, ref. 10006626), as well as negative controls. A positive result
was considered if the Ct values for N1, N2 and RNase P were below 40. Samples
discordant for N1 and N2 were repeated and samples with a Ct ≥ 40 for RNase
P were considered as invalid.
Quantification of antibodies to SARS-CoV-2 by Luminex. To establish ser-
oprevalence, we used a serological assay based on the Luminex technique that has
the benefit of a higher dynamic range than other assays, favoring the quantification
of immunoglobulin levels. We measured antibodies against the Receptor Binding
Domain (RBD) of the spike glycoprotein of SARS-CoV-232, which is, together with
the nucleocapsid protein (NP), one of the most immunogenic antigens. Antibodies
to RBD correlate with neutralizing antibodies33,34 that could be associated with
protection based on studies of other coronaviruses and animal models34–37. The
RBD antigen, kindly donated by the Krammer lab (Mount Sinai, New York)38, was
coupled to magnetic MAGPLEX 6.5 μm COOH-microspheres from Luminex
Corporation (Austin, TX) at a concentration of 40 µg/ml for 10,000 beads/µl39.
Antigen-coupled beads were added to a 96-well μClear® flat bottom plate
(Greiner Bio-One, 655096) at 2000 beads/well in a volume of 90 μL/well of
phosphate buffered saline+ 1% bovine serum albumin+ 0.05% sodium azide
Fig. 3 SARS-CoV-2 antibody levels by demographic and clinical variables. Levels (median fluorescence intensity, MFI) of IgM, IgG, and IgA against
Receptor Binding Domain (RBD) of the SARS-CoV-2 Spike glycoprotein by sex (a), age (b), symptoms (c), and duration of symptoms (d). For (a–c), data
are shown only for seropositive subjects for IgM (N= 36), for IgG (N= 44), and for IgA (N= 47). For (d), data are shown only for seropositive and
symptomatic subjects for IgM (N= 31), for IgG (N= 40), and for IgA (N= 41). Percentages indicate the proportion of seropositive subjects within each
category of the x-axis. The center line of boxes depicts the median of MFIs; the lower and upper hinges correspond to the first and third quartiles; the
distance between the first and third quartiles corresponds to the interquartile range (IQR); whiskers extend from the hinge to the highest or lowest value
within 1.5 × IQR of the respective hinge. Wilcoxon rank test was used to assess statistically significant differences in antibody levels between groups in (a, c
and d). Spearman test was used to calculate the correlation coefficients (r) and p values (p) in (b), where the black line depicts linear regression and the
blue curve represents nonlinear regression calculated using the LOESS (locally estimated scatterplot smoothing) method.
Fig. 4 SARS-CoV-2 antibody levels by time since onset of symptoms in seropositive subjects. Levels (median fluorescence intensity, MFI) of IgM, IgG,
and IgA against Receptor Binding Domain of the SARS-CoV-2 Spike glycoprotein by days since onset of any symptom. Data are shown only for seropositive
subjects with any symptom compatible with COVID-19 (n= 30 for IgM, 39 for IgG, and 40 for IgA). The fitting curve was calculated using the LOESS
(locally estimated scatterplot smoothing) method. Shaded areas represent 95% confident intervals. One subject seropositive for the three isotypes and
who started symptoms 40 days before serological testing is not shown.
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(PBS-BN). Next, 10 μl of test plasma samples (final dilution 1/500), 10 μl of a
positive control (pool of 20 plasmas from subjects with a positive SARS-CoV-2
rRT-PCR, at four dilutions, 1/500, 1/2000, 1/8000 and 1/32000, for QA/QC), and
10 μl of two negative controls (plasmas from European subjects collected before the
COVID-19 pandemic, at 1/500), were added per plate. Two blank control wells
with beads in PBS-BN were set up to measure background signal. Plates were
incubated at room temperature (RT) for 2 h on a microplate shaker at 500 rpm and
protected from light. Plates were washed three times with 300 μl/well of PBS-
Tween20 0.05%, using a magnetic manual washer (Millipore, 43-285). A hundred
microliters of biotinylated secondary antibody diluted in PBS-BN (anti-human
IgG, B1140, 1/1250; anti-human IgM, B1265, 1/1000; or anti-human IgA,
SAB3701227, 1/500; Sigma) were added to all wells and incubated for 45 min at
500 rpm at RT and protected from light. Plates were washed three times and 100 μL
of streptavidin-R-phycoerythrin (Sigma, 42250) diluted 1:1000 in PBS-BN were
added and incubated during 30 min at 500 rpm, RT and protected from light.
Plates were washed three times, and beads resuspended in 100 μl of PBS-BN and
kept overnight at 4 °C, protected from light. The next day, plates were read using a
Luminex xMAP® 100/200 analyzer with 70 μl of acquisition volume per well, DD
gate 5000–25000 settings, and high PMT option. At least 50 beads were acquired
per sample. Crude median fluorescent intensities (MFI) were exported using the
xPONENT software. Assay cutoff was calculated as 10 to the mean plus 3 standard
deviations of log10-transformed MFIs of 47 negative controls. Sensitivity of the
assay using samples from participants previously diagnosed with COVID-19 and
with more than 10 days since the onset of symptoms was 97% for IgA and IgG and
75% for IgM, with specificities of 100% for IgG and IgM and 98% for IgA
(Supplementary table 4). The area under the receiver operating characteristic curve
(AUC) was >0.97 for each of the isotypes using these same samples
(Supplementary Fig. 1a) and >0.87 using samples from any participant previously
diagnosed with COVID-19 regardless of the time since onset of symptoms
(Supplementary Fig. 1b).
Sample size and statistical analysis. In order to assess the seroprevalence against
SARS-CoV-2 at two time points (month 0 and month 1), with a precision of 5%
and a 95% CI, a loss to follow up between month 0 and month 1 of 5% and
assuming that the prevalence at month 0 was 30% and at month 1 was 50%, with a
finite population, we estimated we would need 570 HCW. Given the uncertainty
about what the seroprevalence would be at month 1, we used 50%, which provides
the most conservative sample size.
Seroprevalence of antibodies against SARS-CoV-2, prevalence of SARS-CoV-2
infection by rRT-PCR, and cumulative prevalence of past or current infection
(positive SARS-CoV-2 rRT-PCR and/or antibody seropositivity), were calculated as
proportions with 95% CI. We tested the association between variables with the Chi-
square or Fisher’s exact test (for categorical variables) and T Student test (for
continuous quantitative variables). Univariable and MLM were run to evaluate
factors associated with seroprevalence of antibodies against SARS-CoV-2. For the
variables to be included in the MLM model, we used a stepwise selection, starting
with the full model, and using a p value of 0.10 for removal and 0.05 for addition of
variables. A diagnosis of COVID-19 was excluded from the MLM because it was
assumed to be the source for antibody generation and the high expected correlation
with COVID-19 symptoms reported.
Spearman correlations were performed to assess the association of antibody
levels with age. Wilcoxon Sum Rank test was used to compare the antibody levels
between different groups. Receiver Operating Characteristic (ROC) curves and
their correspondent AUC were calculated using the predicted values estimated by
logistic regression models with MFI for IgM, IgG, IgA or their combination as
predictors and the rRT-PCR result as outcome. The analysis was carried out using
the statistical software Stata v16.1 (College Station, TX: StataCorp LLC) and R
studio version R-3.5.1 (packages used: ggplot2 and pROC).
Ethical considerations. We have complied with all relevant ethical regulations.
The protocol and informed consent form were reviewed and approved by the
Institutional Review Board (IRB) at HCB, (CEIm) prior to study implementation
(Ref number: HCB/2020/0336).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Anonymized data used for this analysis is available and made public under the title of
this publication at http://diposit.ub.edu/dspace/handle/2445/56611.
Code availability
Code used in the analysis is available at http://diposit.ub.edu/dspace/handle/2445/56611.
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